期刊文献+

Impact of age-related comorbidity on results of colorectal cancer surgery 被引量:5

Impact of age-related comorbidity on results of colorectal cancer surgery
下载PDF
导出
摘要 AIM: To analyze the correlation between preexisting comorbidity and other clinicopathological features, short-term surgical outcome and long-term survival in elderly patients with colorectal cancer (CRC). METHODS: According to age, 403 patients operated on for CRC in our department were divided into group A (< 70 years old) and group B (≥ 70 years old) and analyzed statistically. RESULTS: Rectal localization prevailed in group A (31.6% vs 19.7%, P = 0.027), whereas the percentage of R0 resections was 77% in the two groups. Comorbidity rate was 46.2% and 69.1% for group A and B, respectively (P < 0.001), with a huge difference as regards cardiovascular diseases. Overall, postoperative morbidity was 16.9% and 20.8% in group A and B, respectively (P = 0.367), whereas mortality was limited to group B (4.5%, P = 0.001). In both groups, patients who suffered from postoperative complications had a higher overall comorbidity rate, with preexisting cardiovascular diseases prevailing in group B (P = 0.003). Overall 5-year survival rate was significantly betterfor group A (75.2% vs 55%, P = 0.006), whereas no signif icant difference was observed considering disease-specif ic survival (76.3% vs 76.9%, P = 0.674). CONCLUSION: In spite of an increase in postoperative mortality and a lower overall long-term survival for patients aged ≥ 70 years old, it should be considered that, even in the elderly group, a signif icant number of patients is alive 5 years after CRC resection. AIM: To analyze the correlation between preexisting comorbidity and other clinicopathological features, short-term surgical outcome and long-term survival in elderly patients with colorectal cancer (CRC). METHODS: According to age, 403 patients operated on for CRC in our department were divided into group A (〈 70 years old) and group B (≥ 70 years old) and analyzed statistically. RESULTS: Rectal localization prevailed in group A (31.6% vs 19.7%, P = 0.027), whereas the percentage of R0 resections was 77% in the two groups. Comorbidity rate was 46.2% and 69.1% for group A and B, respectively (P 〈 0.001), with a huge difference as regards cardiovascular diseases. Overall, postoperative morbidity was 16.9% and 20.8% in group A and B, respectively (P = 0.367), whereas mortality was limited to group B (4.5%, P = 0.001). In both groups, patients who suffered from postoperative complications had a higher overall comorbidity rate, with preexisting cardiovascular diseases prevailing in group B (P = 0.003). Overall 5-year survival rate was significantly better for group A (75.2% vs 55%, P = 0.006), whereas no significant difference was observed considering diseasespecific survival (76.3% vs 76.9%, P = 0.674). CONCLUSION: In spite of an increase in postoperative mortality and a lower overall long-term survival for patients aged ≥ 70 years old, it should be considered that, even in the elderly group, a significant number of patients is alive 5 years after CRC resection.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第45期5706-5711,共6页 世界胃肠病学杂志(英文版)
关键词 Colorectal cancer ELDERLY Post-operative complications CO-MORBIDITY Aged 并发症 大肠癌 年龄 手术 心血管疾病 存活率 病理特征 统计分析
  • 相关文献

参考文献1

二级参考文献8

共引文献7

同被引文献38

  • 1Richard M G, Neal J M, Josep Tabernero, et al. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer [J]. Gastrointest Cancer, 2009, 3(suppl 2):S23-S27.
  • 2Hanna K S, Richard M G. Colorectal cancer treatment in older patients[J]. Gastrointestinal cancer research, 2007, 1 : 248- 253.
  • 3British Colorectal Collaborative Group. Surgery for eolorectal cancer in elderly patients: a systematic review[J]. Lancet, 2000,356 (9234) : 968- 974.
  • 4MeCardle C S, Hole D J. Outcome following surgery for colorectal cancer[J]. Br Med Bull, 2002,64:119-125.
  • 5Lacy A M, Garcia--Valdecasas J C, Delgado S,et al. Laparoscopy -assisted colectomy versus colectomy for treatment of non-metastatic colon cancer: a randomized trial[J]. Lancet, 2002,359:2224-2229.
  • 6Andre T, Boni C, Navarro M, et al. Improved overall survival with oxalipatin, fluorouracil, and leucovorin as adjuvant treatment in stage Ⅱ or Ⅲ colon cancer in the MOSAIC trial[J]. J Clin, 2009, 27: 3109-3116.
  • 7Twelves C. Capecitabine as adjuvant treatment for stage Ⅲ colon cancer[J]. N Engl J Med, 2005,352: 2696-2704.
  • 8Schrag D, Cramer L D,Bach P B, et al. Age and adjuvant chemotherapy use after surgery for stage Ⅲ colon cancer[J]. J Natl Cancer Inst, 2001,93: 850-857.
  • 9Daniel J S, Richard M G, Stacy D J, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients [J]. N Engl Med,2001, 345(15):1091-1097.
  • 10Folprecht G, Seymour M T, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials[J]. J Clin Oncol, 2008,26: 1443-1451.

引证文献5

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部